¼¼°èÀÇ ¹Ý°íÇüÁ¦ CDMO ½ÃÀå
Semi-Solid Dosage CDMO
»óǰÄÚµå : 1773895
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 464 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,112,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,338,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹Ý°íÇüÁ¦ CDMO ¼¼°è ½ÃÀåÀº 2030³â±îÁö 608¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 335¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹Ý°íÇüÁ¦ CDMO ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 10.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 608¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿Ü¿ëÁ¦´Â CAGR 11.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 365¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °æÇÇÁ¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 9.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 91¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 14.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹Ý°íÇüÁ¦ CDMO ½ÃÀåÀº 2024³â¿¡ 91¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 125¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 14.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 7.5%¿Í 9.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 8.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹Ý°íÇüÁ¦ CDMO ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹Ý°íü Á¦Á¦ CDMO°¡ ÀǾàǰ Á¦Á¶¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¹Ý°íÇüÁ¦ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü(CDMO)Àº Å©¸², °Ö, ¿¬°í, Á¾àÀÇ Ã³¹æ¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» Á¦°øÇÔÀ¸·Î½á Á¦¾à »ê¾÷¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀÌ °³¹ß ¹× Á¦Á¶¸¦ Àü¹® Á¦Á¶¾÷ü¿¡ À§Å¹ÇÏ´Â °¡¿îµ¥, ¹Ý°íÇüÁ¦ CDMO´Â Á¦Ç°ÀÇ ¾ÈÁ¤¼º, »ýüÀÌ¿ë·ü ¹× ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ÆÄÆ®³Ê°¡ µÇ°í ÀÖ½À´Ï´Ù. ÇǺΰú Ä¡·á, °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ, ±¹¼Ò ÁøÅëÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹æÃâ Á¦¾î Á¦Á¦ ¹× ³ª³ë±â¼ú ±â¹ÝÀÇ ¾à¹°Àü´ÞÀÇ ¹ßÀüÀº ¹Ý°íü Á¦Á¦ CDMOÀÇ ºñÁî´Ï½º ±âȸ¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù.

¾î¶² Çõ½ÅÀÌ ¹Ý°íü Á¦Á¦ CDMO ¼­ºñ½º¸¦ º¯È­½Ã۰í Àִ°¡?

À¯È­ ±â¼ú, ¸¶ÀÌÅ©·Îĸ½¶È­, ¸®Æ÷¼Ø ¾à¹°Àü´ÞÀÇ ¹ßÀüÀº ¹Ý°íü Á¦Á¦ÀÇ È¿´ÉÀ» Çâ»ó½Ã۰í ÀÖÀ¸¸ç, AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ¸ðµ¨¸µÀº Á¦Á¦ÀÇ ¾ÈÁ¤¼º°ú Á¦Á¶ È®À强À» ÃÖÀûÈ­ÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬¼Ó Á¦Á¶ ±â¼úÀÇ Ã¤ÅÃÀ¸·Î »ý»ê È¿À²¼ºÀÌ Çâ»óµÇ°í, ºñ¿ëÀÌ Àý°¨µÇ¸ç, ¹èÄ¡ÀÇ ÆíÂ÷°¡ ÃÖ¼ÒÈ­µÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ºÎ»óÀ¸·Î ȯÀÚ ¸ÂÃãÇü ¹Ý°íü Á¦Á¦ÀÇ °³¹ßµµ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ CDMO´Â º¸´Ù Á¤¹ÐÇÏ°í °íǰÁúÀÇ ÀǾàǰÀ» Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¹Ý°íÇüÁ¦ CDMOÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â Ä¡·á ºÐ¾ß´Â?

ÇǺΰú ¿µ¿ªÀº °Ç¼±, ½ÀÁø, ¿©µå¸§ µîÀÇ Áõ»ó¿¡ ´ëÇÑ ±¹¼Ò Ä¡·á ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ¹Ý°íü Á¦Çü CDMOÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÅëÁõ °ü¸® ¹× °æÇÇ ¾à¹°Àü´Þ ºÐ¾ßµµ °æ±¸¿ë ¾à¹°À̳ª ÁÖ»çÁ¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀû Ä¡·á¹ýÀ» ã´Â ȯÀÚµéÀÇ ¼ö¿ä·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. È£¸£¸ó ´ëü¿ä¹ý(HRT)°ú Áú ³» ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ µîÀåÀº ½ÃÀå ¼ö¿ä¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »óó ¹× È­»ó Ä¡·á ºÐ¾ß¿¡¼­´Â Ä¡À¯·Â°ú Ç×±Õ¼ºÀ» °­È­ÇÑ ¹Ý°íü Á¦Á¦ÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

¹Ý°íÇüÁ¦ CDMO ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹Ý°íÇüÁ¦ CDMO ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº Á¦¾à ¾÷°èÀÇ ¾Æ¿ô¼Ò½Ì Æ®·»µå Áõ°¡, ÇǺΰú Ä¡·á ¹× °æÇÇÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¦Á¦ °úÇÐÀÇ ¹ßÀüÀÔ´Ï´Ù. ±ÔÁ¦ ±â°üÀº ǰÁú °ü¸®¿Í GMP(Good Manufacturing Practice)¸¦ °­Á¶Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¦¾à»ç°¡ Àü¹® CDMO¿Í Á¦ÈÞÇÏ´Â °ÍÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï ½ÃÀåÀÇ ¼ºÀå°ú ÀϹÝÀǾàǰ(OTC) ¹Ý°íü Á¦Á¦ÀÇ È®´ë´Â À§Å¹ Á¦Á¶ÀÇ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÊ¿¡ µû¶ó ¹Ý°íÇüÁ¦ CDMOÀÇ ¿ªÇÒÀº ÀǾàǰ °³¹ß ¹× Á¦Á¶¿¡ ÀÖ¾î Á¡Á¡ ´õ Áß¿äÇØÁú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Åõ¿© °æ·Î(±¹¼Ò, °æÇÇ, ±âŸ), Á¦Ç°(¿¬°í, Å©¸² ¹× ·Î¼Ç, ÆäÀ̽ºÆ®, °Ö, ±âŸ), ¼­ºñ½º(°³¹ß ¼öŹ, Á¦Á¶ ¼öŹ), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾àȸ»ç, ¹ÙÀÌ¿À Á¦¾àȸ»ç, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Semi-Solid Dosage CDMO Market to Reach US$60.8 Billion by 2030

The global market for Semi-Solid Dosage CDMO estimated at US$33.5 Billion in the year 2024, is expected to reach US$60.8 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$36.5 Billion by the end of the analysis period. Growth in the Transdermal segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.1 Billion While China is Forecast to Grow at 14.3% CAGR

The Semi-Solid Dosage CDMO market in the U.S. is estimated at US$9.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$12.5 Billion by the year 2030 trailing a CAGR of 14.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Semi-Solid Dosage CDMO Market - Key Trends & Drivers Summarized

Why Are Semi-Solid Dosage CDMOs Gaining Importance In Pharmaceutical Manufacturing?

Semi-solid dosage contract development and manufacturing organizations (CDMOs) are playing a vital role in the pharmaceutical industry by providing expertise in formulating creams, gels, ointments, and suppositories. As pharmaceutical companies seek to outsource development and production to specialized manufacturers, semi-solid dosage CDMOs are becoming critical partners in ensuring product stability, bioavailability, and regulatory compliance. The rising demand for dermatological treatments, transdermal drug delivery systems, and topical pain relief products is further driving market growth. Additionally, advancements in controlled-release formulations and nanotechnology-based drug delivery are expanding the opportunities for semi-solid dosage CDMOs.

What Innovations Are Transforming Semi-Solid Dosage CDMO Services?

Advancements in emulsification technology, microencapsulation, and liposomal drug delivery are enhancing the efficacy of semi-solid pharmaceutical formulations. AI-powered predictive modeling is being used to optimize formulation stability and manufacturing scalability. Additionally, the adoption of continuous manufacturing techniques is improving production efficiency, reducing costs, and minimizing batch variability. The rise of personalized medicine and targeted drug delivery systems is also leading to the development of patient-specific semi-solid formulations. These innovations are enabling CDMOs to offer more precise, high-quality pharmaceutical products.

Which Therapeutic Areas Are Driving The Growth Of Semi-Solid Dosage CDMOs?

The dermatology sector is a major contributor to semi-solid dosage CDMO growth, with increasing demand for topical treatments for conditions such as psoriasis, eczema, and acne. The pain management and transdermal drug delivery segment is also expanding, as patients seek non-invasive alternatives to oral and injectable medications. The rise of hormone replacement therapy (HRT) and vaginal drug delivery systems is further contributing to market demand. Additionally, the wound care and burn treatment segment is driving innovation in semi-solid formulations with enhanced healing and antimicrobial properties.

What Factors Are Fueling The Growth Of The Semi-Solid Dosage CDMO Market?

The growth of the semi-solid dosage CDMO market is being driven by increasing outsourcing trends in the pharmaceutical industry, rising demand for dermatological and transdermal treatments, and advancements in formulation science. Regulatory agencies are emphasizing quality control and Good Manufacturing Practices (GMP), further encouraging pharmaceutical companies to partner with specialized CDMOs. Additionally, the growth of emerging markets and the expansion of over-the-counter (OTC) semi-solid products are creating new opportunities for contract manufacturing. As pharmaceutical innovation continues, the role of semi-solid dosage CDMOs will become increasingly essential in drug development and production.

SCOPE OF STUDY:

The report analyzes the Semi-Solid Dosage CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Topical, Transdermal, Others); Product (Ointments, Creams & Lotions, Pastes, Gels, Others); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â